Sequome engineers biological sequences to develop therapeutics, building on our sequence→function AI, Gene Genie, published on the cover of Nature.
We’re fortunate to have had the opportunity to collaborate with ~half of Top-10 Pharma and Google DeepMind already; and we haven’t even publicly launched yet!
Our investors include former CEOs and leaders from Novartis, Merck, Gilead, RA Capital, and OpenAI, alongside luminary faculty at Harvard & Stanford, and leading AI investors.